Research Topics
| G SchifittoSummaryAffiliation: University of Rochester Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Selegiline and oxidative stress in HIV-associated cognitive impairmentG Schifitto
University of Rochester, NY, USA
Neurology 73:1975-81. 2009....- Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairmentGiovanni Schifitto
Department of Neurology, University of Rochester, Rochester, New York, USA
J Neurovirol 15:176-86. 2009.... - Fatigue in levodopa-naive subjects with Parkinson diseaseG Schifitto
University of Rochester, NY, USA
Neurology 71:481-5. 2008..Fatigue is a common complaint in Parkinson disease (PD). We investigated fatigue in a cohort of previously untreated patients with early PD enrolled in the Earlier vs Later Levodopa (ELLDOPA) clinical trial... 
Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy studyGiovanni Schifitto
University of Rochester, Rochester, New York 14620, USA
AIDS 21:1877-86. 2007..To assess the safety and efficacy of memantine, an uncompetitive antagonist of the N-methyl-D-aspartate receptor as treatment of HIV-associated cognitive impairment...- Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first reportG Schifitto
Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
Neurology 66:919-21. 2006..VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects... - A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairmentG Schifitto
Department of Neurology, Movement and Inherited Neurologic Disorders, Clinical Trials Coordination Center, 1351 Mount Hope Avenue, Suite 223, Rochester, NY 14620, USA
Neurology 69:1314-21. 2007..This rationale has led to the design and implementation of this Selegiline Transdermal System (STS) study with the primary aims of assessing safety and tolerability of STS as well as improvement in cognitive performance... - Markers of immune activation and viral load in HIV-associated sensory neuropathyG Schifitto
Department of Neurology, University of Rochester, 601 Elmwood Ave, Box 673, Rochester, NY 14642, USA
Neurology 64:842-8. 2005..The pathogenesis of DSP is unknown, although both HIV proteins and products of immune activation triggered by HIV infection have been implicated... - A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathyGiovanni Schifitto
University of Rochester, Rochester, New York 14620, USA
J Neurovirol 12:328-31. 2006..Results were similar to those of other pilot studies of memantine for neuropathic pain unrelated to HIV, suggesting that memantine is ineffective for the symptomatic treatment of HIV-associated SDSP... - Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementiaJ J Sevigny
Columbia University and The Taub Institute, New York, NY 10032, USA
Neurology 63:2084-90. 2004.... - A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairmentD B Clifford
Department of Neurology, Washington University, St Louis, MO 63110, USA
Neurology 59:1568-73. 2002..It has neuroprotective properties in model systems for HIV-associated neurotoxicity and thus is a candidate for neuroprotective therapy in humans with HIV-associated CNS disease... - A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291J C McArthur
Department of Neurology, Johns Hopkins University, Baltimore, MD, USA
Neurology 54:1080-8. 2000..To evaluate the safety and efficacy of recombinant human nerve growth factor (rhNGF) in HIV-associated sensory neuropathy (SN) within a multicenter, placebo-controlled, randomized trial (ACTG 291)... - Factors associated with incident human immunodeficiency virus-dementiaY Stern
Department of Neurology and Gertrude H Sergievsky Center, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
Arch Neurol 58:473-9. 2001..Antecedents to human immunodeficiency virus-dementia (HIV-D) are poorly understood... - Inter-rater reliability of a clinical staging of HIV-associated cognitive impairmentK Marder
Department of Neurology, Sergievsky Center, New York, NY 10032, USA
Neurology 60:1467-73. 2003..To determine the inter-rater reliability of a modification of the Memorial Sloan-Kettering (MSK) Staging for HIV-associated cognitive impairment... - Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomesG Schifitto
Department of Neurology, University of Rochester, NY, USA
Neurology 56:415-8. 2001..Modifications of current functional scales or new functional instruments are needed to assess the clinical relevance of cognitive changes in clinical trials of HIV-associated cognitive impairment... - Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled studyN Sacktor
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
Neurology 54:233-5. 2000..Both selegiline and placebo were well tolerated with few adverse events. Improvements favoring the selegiline group were suggested on single tests of verbal memory and motor/psychomotor performance, warranting a larger study... - Autonomic performance and dehydroepiandrosterone sulfate levels in HIV-1-infected individuals: relationship to TH1 and TH2 cytokine profileG Schifitto
Department of Neurology, University of Rochester, 601 Elmwood Ave, Box 673, Rochester, NY 14642
Arch Neurol 57:1027-32. 2000..In animal models, autonomic and endocrine dysfunction are associated with an altered cytokine profile... - Is skin biopsy a predictor of transition to symptomatic HIV neuropathy? A longitudinal studyD N Herrmann
Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
Neurology 66:857-61. 2006.... - Incidence of and risk factors for HIV-associated distal sensory polyneuropathyG Schifitto
Department of Neurology, University of Rochester, Rochester, NY 14642, USA
Neurology 58:1764-8. 2002..To assess the incidence of and risk factors for distal sensory polyneuropathy (DSP) in a cohort of HIV-infected subjects... - Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathyG Schifitto
Department of Neurology, University of Rochester, NY 14642, USA
Neurology 57:1313-6. 2001..However, there was no improvement of neuropathy severity as assessed by neurologic examination, quantitative sensory testing, and epidermal nerve fiber density... - Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trialD M Simpson
Mount Sinai School of Medicine, New York, NY, USA
Neurology 74:413-20. 2010..Pregabalin is effective in several neuropathic pain syndromes. This trial evaluated its efficacy, safety, and tolerability for treatment of painful HIV-associated neuropathy... - Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trialN Sacktor
Department of Neurology, Johns Hopkins Bayview Medical Center, 4940 Eastern Ave, 301 Building, Suite 2100, Baltimore, MD 21224, USA
Neurology 77:1135-42. 2011..We conducted a study of minocycline to assess its safety, tolerability, and efficacy for the treatment of HIV-associated cognitive impairment... - Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathyM Polydefkis
Department of Neurology, Johns Hopkins University, Baltimore, MD, USA
Neurology 58:115-9. 2002..To explore the relationship between intraepidermal nerve fiber (IENF) density in HIV-associated sensory neuropathy (HIV-SN) to measurements of neuropathy severity and progression of HIV disease... 
Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adultsRobert Dicenzo
Wegmans School of Pharmacy, St John Fisher College, Rochester, NY 14618, USA
Ann Pharmacother 43:1972-7. 2009..The central nervous system may act as a sanctuary site for viral replication in the setting of low antiretroviral penetration. Data on lopinavir cerebrospinal fluid (CSF) trough concentration (C(trough)) values have yet to be reported...- Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performanceChristina M Marra
Department of Neurology, University of Washington School of Medicine, Seattle, USA
AIDS 23:1359-66. 2009..To determine whether antiretroviral regimens with good central nervous system (CNS) penetration control HIV in cerebrospinal fluid (CSF) and improve cognition... - Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levelsDavid M Simpson
Department of Neurology, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, Box 1052, New York, NY 10029, USA
AIDS 16:407-12. 2002..Further studies are needed to determine if aggressive use of antiretroviral drugs, including the use of dideoxynucleosides, may be of benefit to prevent or improve peripheral neuropathy... - Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030E R Dorsey
Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Blvd, Suite 223, Rochester, NY 14620, USA
Neurology 68:384-6. 2007..The number of individuals with PD over age 50 in these countries was between 4.1 and 4.6 million in 2005 and will double to between 8.7 and 9.3 million by 2030... - Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidantsJ Turchan
Department of Neurology, Pharmaceutical Sciences, University of Kentucky, Lexington, USA
Neurology 60:307-14. 2003..The authors have identified several novel compounds that are capable of blocking the CSF-induced toxicity, the therapeutic potential of which is worthy of further exploration... - Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individualsGiovanni Schifitto
University of Rochester, Rochester, NY, USA
J Neurovirol 17:17-25. 2011..This observation, taken together with the association between fatigue and neuropsychological tests of frontal lobe performance is consistent with the hypothesis of a striatal-cortical circuitry involvement in the symptoms of fatigue... - Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavirRobert Dicenzo
University at Buffalo, Buffalo, New York, USA
Antimicrob Agents Chemother 52:3035-9. 2008..2). Minocycline coadministration resulted in decreased atazanavir exposure, and there was no evidence that the addition of valproic acid mediated this effect... - Epidermal nerve fiber density, axonal swellings and QST as predictors of HIV distal sensory neuropathyDavid N Herrmann
Department of Neurology, University of Rochester, SMH 601 Elmwood Avenue, Box 673, Rochester, New York 14642, USA
Muscle Nerve 29:420-7. 2004..03, 95% CI 1.01-1.05) were the only two measures associated with a shorter time to development of symptomatic DSP. Quantitation of ENF swellings and heat pain thresholds deserve further study as predictors of symptomatic neuropathy... - Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adultsRobert Dicenzo
University of Rochester Medical Center, Clinical Pharmacology Unit, 601 Elmwood Ave, Box 315, Room 1 6124, Rochester, NY 14642, USA
Antimicrob Agents Chemother 48:4328-31. 2004..LPV concentrations tended to be higher when the drug was combined with VPA. Results of VPA comparisons fail to raise concern that coadministration with EFV or LPV/r will significantly influence trough concentrations of VPA... - Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapyJustin C McArthur
Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 7609, USA
Arch Neurol 61:1687-96. 2004..Before the introduction of combination antiretroviral therapy (CART), neurological disease correlated with cerebrospinal fluid (CSF) levels of human immunodeficiency virus (HIV) RNA... - HIV-associated cognitive impairment before and after the advent of combination therapyNed Sacktor
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
J Neurovirol 8:136-42. 2002..Even though HAART has reduced the incidence of HIV dementia, HIV-associated cognitive impairment continues to be a major clinical problem among individuals with advanced infection... - Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDSStephen Dewhurst
Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA
J Neuroimmune Pharmacol 2:93-6. 2007..These findings highlight the therapeutic potential of GSK-3beta blockade... - Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activationZiye Sui
Interdepartmental Program in Neuroscience, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
J Immunol 177:702-11. 2006..In aggregate, our data define MLK3 as a promising therapeutic target for intervention in HAD... - An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infectionJeffrey J Sevigny
Department of Neurology and Gertrude H Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA
Arch Neurol 64:97-102. 2007..Several markers of immune activation have been identified as potential prognostic markers for human immunodeficiency virus (HIV)-associated morbidity and mortality, but the results from studies are conflicting... - A multicenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementiaNed Sacktor
Department of Neurology, Johns Hopkins Bayview Medical Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
J Magn Reson Imaging 21:325-33. 2005..To evaluate single-voxel proton magnetic resonance spectroscopy (SV-MRS) and magnetic resonance spectroscopic imaging (MRSI) metabolite results in individuals with HIV dementia... - Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementiaZiye Sui
Interdepartmental Program in Neuroscience, University of Rochester School of Medicine, 601 Elmwood Avenue, Rochester, NY 14642, USA
J Immunol 178:3226-36. 2007..Taken together, our results show that CD40 signaling in microglia and monocytes can synergize with the effects of Tat, further amplifying inflammatory processes within the CNS and influencing neuronal survival... - Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificityRobert H Paul
Department of Behavioral Neuroscience, University of Missouri, St Louis, St Louis, MO 63121, USA
J Neuropsychiatry Clin Neurosci 19:283-92. 2007..Prospective studies are needed to elucidate the evolution of these changes in the setting of antiretroviral therapy... - A multi-center 1H MRS study of the AIDS dementia complex: validation and preliminary analysisPatricia Lani Lee
NMR Center, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02111, USA
J Magn Reson Imaging 17:625-33. 2003.... - Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090Scott R Evans
Harvard School of Public Health, Boston, Massachusetts, USA
HIV Clin Trials 8:437-46. 2007..To assess the long-term safety (primary aim) and efficacy (secondary aim) of the MAO-B inhibitor Selegiline Transdermal System (STS) for the treatment of HIV-associated cognitive impairment... - Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus -associated dementiaLynn M Wachtman
Department of Molecular and Comparative Pathobiology, The Johns Hopkins University, Baltimore, Maryland 21287 7609, USA
Arch Neurol 64:1264-72. 2007..The identification of biomarkers identifying onset of human immunodeficiency virus-associated dementia (HIV-D) is critical for diagnosis and the elucidation of pathophysiologic pathways... - Chronic stress in nonelderly caregivers: psychological, endocrine and immune implicationsKavita Vedhara
MRC Health Services Research Collaboration, Department of Social Medicine, University of Bristol, Canynge Hall, UK
J Psychosom Res 53:1153-61. 2002..g., spousal caregivers of dementia patients) extends to a younger caregiver population, specifically spousal carers of patients with multiple sclerosis (MS)... - Regional patterns of brain metabolites in AIDS dementia complexConstantin T Yiannoutsos
Division of Biostatistics, Indiana University School of Medicine, 1050 Wishard Boulevard, RG 4101, Indianapolis, IN 46202, USA
Neuroimage 23:928-35. 2004..We conclude that by using factor analysis, we are able to combine multiple metabolites across brain regions in a biologically plausible manner and construct a predictive model of ADC adjusting for relevant factors such as age...
Research Grants
- Selegiline, Oxidative Stress and MRS in HIV DementiaGiovanni Schifitto; Fiscal Year: 2003..The proposed study will take advantage of the ACTG supporting A5090 study and of the existing MRS consortium infrastructure that will allow us to perform multicenter MRS studies. ..